Dr Park presents at ASCO 2016, the results of a National Cancer Institute (NCI) funded phase III trial performed by the Children’s Oncology Group which found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient’s own stem cells) to standard therapy improves outcomes for these patients.
Read the news story and watch the video interview for more.